Farther Finance Advisors LLC Acquires 225 Shares of Illumina, Inc. $ILMN

Farther Finance Advisors LLC raised its holdings in Illumina, Inc. (NASDAQ:ILMN) by 9.8% during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 2,521 shares of the life sciences company’s stock after acquiring an additional 225 shares during the quarter. Farther Finance Advisors LLC’s holdings in Illumina were worth $241,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently bought and sold shares of ILMN. Rise Advisors LLC grew its position in Illumina by 173.6% in the 1st quarter. Rise Advisors LLC now owns 353 shares of the life sciences company’s stock valued at $28,000 after acquiring an additional 224 shares during the last quarter. Rakuten Securities Inc. lifted its holdings in shares of Illumina by 290.3% in the 1st quarter. Rakuten Securities Inc. now owns 363 shares of the life sciences company’s stock worth $29,000 after buying an additional 270 shares during the period. Center for Financial Planning Inc. purchased a new stake in shares of Illumina in the 1st quarter worth $33,000. PFS Partners LLC lifted its holdings in shares of Illumina by 400.0% in the 1st quarter. PFS Partners LLC now owns 500 shares of the life sciences company’s stock worth $40,000 after buying an additional 400 shares during the period. Finally, Golden State Wealth Management LLC lifted its holdings in shares of Illumina by 123.2% in the 1st quarter. Golden State Wealth Management LLC now owns 529 shares of the life sciences company’s stock worth $42,000 after buying an additional 292 shares during the period. Institutional investors own 89.42% of the company’s stock.

Illumina Trading Up 3.4%

Shares of NASDAQ:ILMN opened at $94.97 on Wednesday. The business’s 50-day moving average is $99.42 and its 200 day moving average is $89.55. Illumina, Inc. has a 1 year low of $68.70 and a 1 year high of $156.66. The firm has a market capitalization of $14.60 billion, a P/E ratio of 12.02, a P/E/G ratio of 2.22 and a beta of 1.43. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.81 and a quick ratio of 1.41.

Illumina (NASDAQ:ILMN) last announced its earnings results on Thursday, July 31st. The life sciences company reported $1.19 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.02 by $0.17. Illumina had a return on equity of 28.93% and a net margin of 29.36%.The company had revenue of $1.06 billion for the quarter, compared to analyst estimates of $1.12 billion. During the same period in the prior year, the company posted $0.36 EPS. The firm’s quarterly revenue was down 4.8% compared to the same quarter last year. Illumina has set its FY 2025 guidance at 4.450-4.55 EPS. On average, research analysts predict that Illumina, Inc. will post 4.51 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have weighed in on ILMN shares. Stephens set a $110.00 target price on Illumina and gave the stock an “overweight” rating in a report on Monday, August 4th. Wall Street Zen cut Illumina from a “buy” rating to a “hold” rating in a report on Saturday, August 2nd. Canaccord Genuity Group upped their target price on Illumina from $99.00 to $105.00 and gave the stock a “hold” rating in a report on Friday, August 1st. Robert W. Baird upped their target price on Illumina from $84.00 to $105.00 and gave the stock a “neutral” rating in a report on Monday, July 28th. Finally, Evercore ISI upped their target price on Illumina from $116.00 to $128.00 and gave the stock an “outperform” rating in a report on Tuesday, July 8th. Six research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, Illumina has an average rating of “Hold” and an average target price of $123.06.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.